MiWendo Solutions, Kamleon and Corify Care share their experiences at the annual workshop of the interuniversity PhD Program in Bioinformatics CREB UPC participated in the digital Workshop of the Interuniversity PhD Program in Bioinformatics, a session where the students defended their thesis in three minutes, but also had an opportunity to learn from other voices in the industry. Open by Toni Manzano from Aizon, the conference included the roundtable “Entrepreneurship in the Healthtech Industry”, where different start-ups’ promoters shared their experience. Marta Guardiola, Co-Founder and CTO of MiWendo Solutions, Jordi Ferré, Co-Founder and CEO of Kamleon and Andreu Climent, Associate Founder and CEO of Corify Care talked from their experience and gave some unique tips to the futureentrepreneurs in the healthtech ecosystem. “I would recommend current generations to identify and talk to the companies that are trying to innovate in their field. It would be stimulating to learn from these possible partners, as well as paying attention to the Key Opinion Leaders in the Science area”, explained Andreu Climent from Corify Care, start-up company, which is going to introduce a novel medical device to non-invasively map cardiac arrhythmias in real time. The speakers also discussed the challenges faced during the incubation process and the time needed to transform an idea into a product. “In our case, it took us around four to five years to bring our technology to the market, but it depends on every project and product”, commented Jordi Ferré, from Kamleon, science-based early-stage company developing user-centered technologies to empower healthier lives by democratizing the monitoring of wellbeing.  Thinking outside the lab and bringing technology to the market sometimes seems to be the hardest part, nevertherless it is not the only key to success. “A well-balanced team, with all the expertise needed to develop the project, is essential”, […]
The MITEF Spain Jury has reached this decision considering their business model, technology, market potential and evolution, and the team itself. They have developed a technology that is capable of sequencing RNA, from a small blood sample, and associating the expression of genes in more than 320 metabolic pathways that act as biomarkers of the parameters of the individual’s body, analyzing all those variations that are out of the ordinary to improve and prevent health problems. This project was born as a result of the doctoral thesis, defended at the UPC, of ​​the researcher Emma Roca, a biochemist and elite ultra-distance runner. Roca wanted to analyze the impact of high intensity sport on the runners of an ultra-Trail together with Dr. Jose Manuel Soria, principal investigator of the Genomics of Complex Diseases Research Group of the IIB Sant Pau – Fundació Institut de Recerca Hospital de Sant Pau – Centre CERCA and Dr. Alexandre Perera, physicist, expert in Artificial Intelligence and director of the CREB|UPC, in charge of developing the algorithms that allow the expression of metabolic pathways to be automatically evaluated. Finally, within the framework of the Collider program, in the 2019 edition, Dr. Teresa Tarragó, CEO of the project, and Pol Cervera, director of operations, joined in to give the business perspective and face the market. Congratulations to the whole Exheus Team! Awesome work!
The improvement of the quality and life expectation of people with rare diseases was the goal of the La Marató 2019. Along the year, different research projects applied to these funds and finally three of the projects receiving funds will be participated by CREB UPC research groups. These are the following:  ”Use of artificial intelligence and biology systems for the diagnosis and personalized risk assessment for inherited kidney disease, focusing on Alport syndrome”, in which Montserrat Vallverdú Ferrer along with more B2SLab researchers are involved. This project counts with a 399.312,50 € funding. “ArmTracker: A portable system for assessing motor function of the upper extremities during daily life for patients with Duchenne muscular dystrophy and spinal muscular atrophy”,  in whichJosep Maria Font Llagunes along with several BIOMEC & BIOART researchers are involved. This project counts with a 364.053,75 € funding. “Development of personalized treatments in rare genetic diseases causing pediatric parkinsonism”, led by Angels Garcia Cazorla and supported by B2SLab & BIOART researchers, among other. This project counts with a 361.752,49 € funding. Congratulations to our researchers and partners and of course, congratulations to the rest of the projects.
Share4Rare has very nice support for patient profiles with a diagnosis. They will find that Share4Rare is a system in which they can interact, communicate, and share knowledge with other users sharing the same diagnosis. It will also bridge the user to the most relevant patient organizations according to its disease.  There is however the case of undiagnosed rare disease patients. These patients form distinct populations, with specific needs, but also similar experiences and worries to those of the diagnosed patients. However the provision of resources, the access to and availability of information and the means for sharing experiences and questions for this collective are absent or, at most, scarce.  The question for Share4Rare is whether the platform could benefit the undiagnosed populations by exploiting its AI-based design. This design aims to foster the knowledge on rare diseases through collaborative intelligence built on equity principles. The more information the user shares with the community, the more information the platform can provide in return, under strict confidentiality, privacy, and ethical guarantees. https://www.share4rare.org/news/case-undiagnosed-profiles-share4rare
On November 3, the Executive Secretary of ACCIÓ signed the resolution accrediting the TECNIO entities with the new TECNIO qualitity brand. One of them is the Research Center for Biomedical Engineering – CREB, that will certificate this quality until December 31, 2023. TECNIO accreditation allows technology developers as CREB UPC the following: using the TECNIO brand; getting visibility through the ACCIÓ website and other communication tools; getting information about ACCIÓ supporting activities and instruments; tutoring and advising on international cooperation and innovation; participating in programs managed by ACCIÓ; networking and / or marketing activities. TECNIO is the accreditation granted by the Generalitat of Catalonia through ACCIÓ to identify and give visibility to the technology developers of the R&D&I system of Catalonia.  This should help to encourage the activity of the Catalan technology market among technology generators, buyers, facilitators, and other collaborators in the process, such as consultants and business schools.